Protein A Magnetic Beads (ab214286)
Key features and details
- Sample type: Cell Lysate, Serum
Overview
-
Product name
Protein A Magnetic Beads -
Sample type
Serum, Cell Lysate -
Species reactivity
Reacts with: Mouse, Rabbit, Horse, Guinea pig, Hamster, Cow, Human, Pig
Does not react with: Rat, Sheep, Goat, Chicken -
Product overview
Features:
Easy to use, high-binding capacity, non-adherent beads.
Support Characteristics: Paramagnetic, spherical, 6 % cross-linked agarose.
Ligand: Recombinant Protein A.
Particle Size: 75 – 150 µm.
Binding Capacity: Generally >25 mg human IgG/ml wet beads.
Working Temperature: Room temperature.
Storage Solution: PBS with 0.02% Sodium Azide.
Storage Temperature: 4 – 8 °C.
Applications:
Useful for immunoprecipitation and enrichment of IgG antibodies.
High affinity for Fc region of IgG antibodies from a variety of species.
Protein A binds to most human and mouse IgG subclasses (e.g., human IgG1, IgG2, IgG4; mouse IgG1, IgG2a, IgG2b, IgG3).
It also binds to total IgG from cow, guinea pig, hamster, horse, pig, and rabbit. Protein A has little affinity to chicken, goat, rat and sheep.
-
Notes
This product is manufactured by BioVision, an Abcam company and was previously called 6507 Protein A Magnetic Beads. 6507-1 is the same size as the 1 ml size of ab214286.
Description:
Protein A Magnetic Beads are prepared by covalently coupling Recombinant Protein A to 6% crosslinked magnetically beaded agarose. The coupling technique is optimized to give a high binding capacity for IgG. The capacity of IgG binding is generally greater than 25 mg of human IgG per ml of wet gel.
SUGGESTED PROTOCOL:
Prepare the antibody solution by diluting the required amount of antibody in binding buffer before running the protocol.
1. Magnetic Bead Preparation (perform three times)
a. Dispense the required amount of magnetic beads into a 1.5 ml microfuge tube.
b. Place the tube in the magnetic rack and remove the storage solution.
c. Add 500 µl binding buffer.
d. Resuspend the beads.
e. Remove the liquid
2. Antibody Capture
a. Immediately add the antibody solution.
b. Resuspend and mix (slow end-over-end) for at least 15 minutes.
c. Remove the liquid.
3. Washing
a. Add 500 µl Binding Buffer containing 0.5 M NaCl; Remove the liquid.
b. Add 500 µl Binding Buffer; Remove the liquid.
4. Target Binding
a. Add sample diluted in binding buffer.
b. Incubate with slow end-over-end mixing for up to 60 minutes.
c. Remove and collect unbound fraction.
5. Washing ( perform three times)
a. Add 500 µl wash buffer
b. Remove liquid (save washes to troubleshoot)
6. Elution (perform three times)
a. Add 2 volumes elution buffer (vs. bead volume).
b. Completely resuspend beads and incubate at least 2 minutes.
c. Remove and collect elution fraction.
RECOMMENDED BUFFER EXAMPLES:
Binding buffer: 50 mM Tris, 150 mM NaCl, pH 7.5
Wash buffer: 50 mM Tris, 150 mM NaCl, pH 7.5 (or add 1% Octylglucoside to this buffer) (Could also try 1X PBS as both binding and wash buffer)
Elution buffer: 0.1 M -0.2 M Glycine pH 2.5-3.1 (or 0.1 M citric acid, pH 2.5-3.1 or 2.5 % Acetic Acid)
-
Tested applications
Suitable for: Purification, IPmore details
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Components 1 ml Protein A magnetic beads 1 x 1ml
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab214286 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Purification |
Use at an assay dependent concentration.
|
|
IP |
Use at an assay dependent concentration.
|
Notes |
---|
Purification
Use at an assay dependent concentration. |
IP
Use at an assay dependent concentration. |
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (5)
ab214286 has been referenced in 5 publications.
- Chen X et al. Targeting the CtBP1-FOXM1 transcriptional complex with small molecules to overcome MDR1-mediated chemoresistance in osteosarcoma cancer stem cells. J Cancer 12:482-497 (2021). PubMed: 33391445
- Samuels TJ et al. Neuronal upregulation of Prospero protein is driven by alternative mRNA polyadenylation and Syncrip-mediated mRNA stabilisation. Biol Open 9:N/A (2020). PubMed: 32205310
- Xu J et al. Globular C1q Receptor (gC1qR/p32/HABP1) Suppresses the Tumor-Inhibiting Role of C1q and Promotes Tumor Proliferation in 1q21-Amplified Multiple Myeloma. Front Immunol 11:1292 (2020). PubMed: 32760394
- Wei L et al. Novel urokinase-plasminogen activator inhibitor SPINK13 inhibits growth and metastasis of hepatocellular carcinoma in vivo. Pharmacol Res 143:73-85 (2019). PubMed: 30862605
- Meng D et al. MicroRNA-645 targets urokinase plasminogen activator and decreases the invasive growth of MDA-MB-231 triple-negative breast cancer cells. Onco Targets Ther 11:7733-7743 (2018). PubMed: 30464522